Business
Add as a preferred source on GoogleAdjusted diluted EPS was $3.82, while immunology revenue rose 16.3% to $9.165 billion.
AbbVie raised its 2026 earnings outlook after reporting third-quarter revenue of $17.4 billion, up 10.3% year over year, and adjusted diluted earnings per share of $3.82.
The company set its new 2026 adjusted diluted EPS range at $13.95 to $13.99, compared with the previous range of $13.76 to $13.96.
The immunology portfolio brought in $9.165 billion worldwide, a reported gain of 16.3% against the year-earlier quarter.
The Reshaping for Sustainable Growth programme targets $1.5 billion in annualized pre-tax run-rate benefits, with up to $2 billion in one-time restructuring costs.
Q2 sales reached €11.597 billion, while business earnings per share rose 33.3% at CER. Sanofi's calendar lists its next full-year results date for Jan. 28, 2027.
The board approved a ₹1-per-share interim dividend, and first-half capital expenditure was 20% of revenue.
